Asthma and copd research centre
Welcome,         Profile    Billing    Logout  
 2 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chaudhuri, Rekha
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1719
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
09/25
09/25
SAMBA, NCT04680611: Severe Asthma, MepolizumaB and Affect: Study

Recruiting
N/A
120
Europe
no study intervention. Patients receive standard clinical care, no intervention. observational study
University Hospital Southampton NHS Foundation Trust, Portsmouth Hospitals NHS Trust, University of Derby
Severe Eosinophilic Asthma, Psychological Distress, Anxiety, Depression, Psychological Stress, Psychological Adjustment, Psychological Disorder, Psychosocial Problem, Psychosocial Stressor, Psychological, Emotions, Emotional Disorder, Emotional Dysfunction, Emotional Distress, Adjustment, Adjustment, Emotional, Coping Behavior
12/24
12/24
RAPID, NCT04287621: Registry of Asthma Patients Initiating DUPIXENT®

Active, not recruiting
N/A
718
Europe, Canada, Japan, US
DUPIXENT®, dupilumab, REGN668, SAR231893
Regeneron Pharmaceuticals, Sanofi
Asthma
05/26
05/26
SHINE, NCT05130320: Severe Asthma Covid Vaccine Response Study

Recruiting
N/A
250
Europe
Not Interventional their treatments are their routine NHS care
University Hospital Southampton NHS Foundation Trust, Asthma Allergy & Inflammation Research Trust
Coronavirus Antibody Levels
03/22
03/22
Yang, Freda
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chaudhuri, Rekha
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1719
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
09/25
09/25
SAMBA, NCT04680611: Severe Asthma, MepolizumaB and Affect: Study

Recruiting
N/A
120
Europe
no study intervention. Patients receive standard clinical care, no intervention. observational study
University Hospital Southampton NHS Foundation Trust, Portsmouth Hospitals NHS Trust, University of Derby
Severe Eosinophilic Asthma, Psychological Distress, Anxiety, Depression, Psychological Stress, Psychological Adjustment, Psychological Disorder, Psychosocial Problem, Psychosocial Stressor, Psychological, Emotions, Emotional Disorder, Emotional Dysfunction, Emotional Distress, Adjustment, Adjustment, Emotional, Coping Behavior
12/24
12/24
RAPID, NCT04287621: Registry of Asthma Patients Initiating DUPIXENT®

Active, not recruiting
N/A
718
Europe, Canada, Japan, US
DUPIXENT®, dupilumab, REGN668, SAR231893
Regeneron Pharmaceuticals, Sanofi
Asthma
05/26
05/26
SHINE, NCT05130320: Severe Asthma Covid Vaccine Response Study

Recruiting
N/A
250
Europe
Not Interventional their treatments are their routine NHS care
University Hospital Southampton NHS Foundation Trust, Asthma Allergy & Inflammation Research Trust
Coronavirus Antibody Levels
03/22
03/22
Yang, Freda
No trials found

Download Options